DJIA 17,596.35 0.00 0.00%
NASDAQ 4,958.47 0.00 0.00%
S&P 500 2,057.64 0.00 0.00%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog

Sarepta Therapeutics' (SRPT) CEO Ed Kaye on Q1 2015 Results - Earnings Call Transcript

Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT) Q1 2015 Results - Earnings Call Webcast

Why Sarepta Therapeutics, Inc. Shares Soared Today

Sarepta Therapeutics, Inc. shares jumped after it got a Wall Street upgrade.

Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review

Steven Cohen Keeps on Buying Biotechnological Companies

Here's What's Next as BioMarin Moves Closer to Duchenne Drug Approval

10 Most Hated Companies in Healthcare

When emotional trading is on display, the short-sellers come out to play. Find out which companies are the most hated in healthcare, why they're so universally disliked, and which company may eventually deserve a reprieve.

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

See More Articles...